|
Phase I Study of Erlotinib in Patients With Solid Tumors and Hepatic or Renal Dysfunction
Background:
Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This is a Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
Location/Contacts:
California
San Francisco
UCSF Cancer Center and Cancer Research Institute
Alan Paul Venook, MD
Ph: 415-476-2201
1-800-8664 District of Columbia
Washington
Lombardi Cancer Center
Edward Gelmann, MD
Ph: 202-687-2490
gelmann@georgetown.edu Illinois
Chicago
University of Chicago Cancer Research Center
Gini F. Fleming, MD
Ph: 773-702-6712
1-888-824-0200 Iowa
Iowa City
Holden Comprehensive Cancer Center
Gerald H. Clamon, MD
Ph: 319-356-1932
1-800-777-8442 Maryland
Baltimore
Marlene and Stewart Greenebaum Cancer Center, University of Maryland
Martin Edelman, MD
Ph: 410-328-2703
medelman@umm.edu New Hampshire
Lebanon
Norris Cotton Cancer Center
Lionel D. Lewis, MD
Ph: 603-650-6300
1-800-639-6918 Marc Stguart Ernstoff, MD
Ph: 603-650-5534
1-800-639-6918
Marc.S.Ernstoff@hitchcock.org New York
Manhasset
North Shore University Hospital
Daniel R. Budman, MD
Ph: 516-562-8958 New Hyde Park
Long Island Jewish Medical Center
Marc Laurence Citron, MD
Ph: 718-470-8930
citron@lij.edu North Carolina
Winston-Salem
Comprehensive Cancer Center at Wake Forest University
David Duane Hurd, MD
Ph: 336-716-2088 Ohio
Columbus
Arthur G. James Cancer Hospital - Ohio State University
Clara D. Bloomfield, MD
Ph: 614-293-7518
1-800-293-5066
bloomfied-1@medctr.osu.edu
|
